Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck has planned to phase out operations at eight research sites and eight manufacturing sites, and intends to continue to consolidate office facilities worldwide, as part of the merger restructuring program that began last December.
Subscribe to our email newsletter
Merck said that this restructuring is done to create a flexible R&D organisation that facilitates external collaboration and drives pipeline progress and a fully utilised manufacturing supply chain to support Merck’s product portfolio.
As part of the initial phases of its merger restructuring program, Merck is expected to reduce its work force by 15% across all areas of the combined company and continue to hire new employees in strategic growth areas of the business as necessary.
Merck said that it will comply with all local laws and regulations, including where applicable, any requirements to inform or consult with works councils, trade unions or other employee representative bodies.
Richard Clark, chairman and CEO of Merck, said: “These changes are crucial to drive future growth. While we believe these actions are necessary to support Merck’s competitive advantage, they required difficult decisions that will impact some of our colleagues, their families and local communities. We will implement our restructuring plans with care and respect for the employees of Merck.”